<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335617</url>
  </required_header>
  <id_info>
    <org_study_id>MiFlaPRO_2019</org_study_id>
    <nct_id>NCT04335617</nct_id>
  </id_info>
  <brief_title>Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis</brief_title>
  <acronym>MiFlaPRO</acronym>
  <official_title>A Multicenter, Randomized, Double Blind Placebo Controlled Trial of Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servier Affaires Médicales</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation proctitis is an inflammation of rectal mucosa, a complication following radiation
      therapy for cancers of the prostate, cervix, uterus, bladder and other malignancies in the
      pelvic area. Around 20 % of radiaton patients develop radiation proctitis. There is a
      significant lack of trial treatments for radiation proctitis, even more, the studies often
      are small and single center designed or case series. In 2 recent reviews pointing out the
      management of radiation proctitis (2018 and 2016) a summary of current options in therapy
      according to current scientific knowledge is given. Unfortunately, these studies are about
      interventional options with the serious risk of complication. Only little data and lack of
      significance in smaller series onconservative strategies are given.

      We therefore try to implement the anti-inflammatory medication as a 'conservative part' in
      the management and every grade of radiation proctitis - concomitant to eventual need of
      endoscopic intervention or surgery.

      Daflon® is described with potent anti-inflammatory mucosal capacity reducing bleeding, pain
      and urgency symptoms in patients with hemorrhoidal and/or postoperative symptoms. It is shown
      to have a low risk of adverse event or pharmacological interaction and is therefore an
      ethical justified medication for the clinical trial. By using a placebo instead of
      comparative oral medications (with low evidence) this study might illustrate clinical
      significance of expected results as well as information on the natural history of radiation
      proctitis.

      The goal of the study is to compare the number of necessary interventions required to stop
      radiation proctitis inducing rectal bleeding in patients receiving Daflon® in comparison to
      patients in the control group receiving Placebo within 12 months of medical treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">August 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 26, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multicenter, randomized, double-blind, placebo-controlled Phase III study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>In this double blinded study Daflon and placebo are packed in the same manner, the blind is also protected by randomization. Only the principal investigator can break the blind in case of ethical or threatening patterns by contacting the sponsor and clinical research item.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of necessary interventions to stop radiation proctitis</measure>
    <time_frame>Day 1- Day 360</time_frame>
    <description>Number of necessary surgical or interventional treatments required to stop radiation proctitis inducing macroscopic rectal bleeding. Surgical treatment is defined as a surgery with the intention to stop rectal bleeding which occurred due to the radiation proctitis. Interventional treatment is defined as an intervention (endoscopically or proctoscopically) with the intention to stop rectal bleeding which occurred due to the radiation proctitis. e.g. laser therapy, argon plasma coagulation, radiofrequency ablation, cryotherapy, topical formalin, hemostyptic materials like sprays or sponges.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life EORTC QLQ C30 + PRT 20</measure>
    <time_frame>Day 0 -Day 180 -Day 360</time_frame>
    <description>Differences in EORTC QLQ C30 +PRT 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples</measure>
    <time_frame>Day 0-Day 360</time_frame>
    <description>Differences in serum hemoglobin, thrombocytes, coagulation parameters (quick/pt=prothrombin time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool</measure>
    <time_frame>Day 0-Day 360</time_frame>
    <description>Differences in calprotectin stool level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology</measure>
    <time_frame>Day 0-Day 360</time_frame>
    <description>Differences in presence of histological alterations, e.g. distortion of crypts, inflammation of crypts, fibrosis and ectasia of vessels, cytokines.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Proctitis Radiation</condition>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Daflon 500mg for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive Placebo for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daflon</intervention_name>
    <description>500mg fil-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days follwed by 2 tablets daily, one at midday and one in the evening</description>
    <arm_group_label>Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days follwed by 2 tablets daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent form

          -  male and female patients

          -  age ≥ 18 years

          -  patients with diagnosis of radiation proctitis with macroscopic bleeding

          -  end of radiotherapy ≥ 3 month = 90 days ago

        Exclusion Criteria:

          -  infectious proctitis

          -  ulcerative proctitis (inflammatory bowel disease)

          -  persons unable to understand the informed consent

          -  persons, who are in dependent relationship with the study investigators or Sponsor

          -  pregnant or lactating women

          -  participation in an interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Irmgard Kronberger, MD</last_name>
    <phone>+43 512 504</phone>
    <phone_ext>80823</phone_ext>
    <email>irmgard.kronberger@i-med.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marijana Ninkovic, MD</last_name>
    <phone>+43 512 504</phone>
    <phone_ext>80761</phone_ext>
    <email>marijana.ninkovic@i-med.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krankenhaus der Stadt Dornbirn</name>
      <address>
        <city>Dornbirn</city>
        <zip>6850</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clemens Obwegeser, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barmherzige Brüder Krankenhaus Graz</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Mitteregger, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martina Lemmerer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irmgard Kronberger, Dr.</last_name>
      <email>irmgard.kronberger@i-med.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Krems</name>
      <address>
        <city>Krems</city>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Sattler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrike Enkner, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepleruniversität Linz</name>
      <address>
        <city>Linz</city>
        <zip>4040</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Günther Klimbacher, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tulln</name>
      <address>
        <city>Tulln</city>
        <zip>3430</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alf-Dorian Binder, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salzkammergut Klinikum Vöcklabruck</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raimund Strouhal, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Riss, Assoc.-Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nord, Klinik Floridsdorf</name>
      <address>
        <city>Wien</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zacaria Sow, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proctitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

